22157.jpg
Global Epilepsy Drugs Market (2020 to 2027) - Featuring UCB, Eisai, H. Lundbeck and GW Pharmaceuticals
15. September 2021 04:28 ET | Research and Markets
Dublin, Sept. 15, 2021 (GLOBE NEWSWIRE) -- The "Epilepsy Drugs Market, Global Forecast, Impact of COVID-19, Industry Trends, by Drugs Category, Growth, Opportunity Company Analysis" report has been...
Medium Juva Logo (002).png
Juva Life Enrolls First Human Subject in Cannabis Registry Study
09. März 2021 04:30 ET | Juva Life Inc.
VANCOUVER, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California-based life science...
22157.jpg
United States $13.39 Billion Cannabidiol (CBD) Market to 2024 - Growth Drivers / Key Trends & Developments / Challenges
26. Oktober 2020 07:18 ET | Research and Markets
Dublin, Oct. 26, 2020 (GLOBE NEWSWIRE) -- The "US Cannabidiol (CBD) Market (by Types, Distribution Channels & Products): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)"...
Epilepsy Foundation
Epilepsy Foundation Testifies Before FDA Advisory Committee in Support of Potential First-Ever Cannabidiol Drug to Treat Dravet Syndrome
19. April 2018 12:07 ET | Epilepsy Foundation
WASHINGTON, April 19, 2018 (GLOBE NEWSWIRE) -- Philip Gattone, president and CEO of the Epilepsy Foundation, along with other epilepsy advocates, today testified at the U.S. Food & Drug...